Please find attached herewith details of Analyst/Investor meet.

August 7, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – Intimation of Investor/Analyst Meeting With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would liketoinformthedetailsofInvestor/Analystmeetwhichwillbeattendedbytherepresentativesof the Company: Date Name Mode Place Type of Meeting August 12, 2026 Emkay Confluence - In-Person Mumbai Group/One on One Conference The schedule and mode of meeting may undergo a change due to exigencies on part of the Investor/Analyst/Company. You are requested to kindly take a note of the same. Thanking You, Yours Sincerely, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office: Registered Office: Technopolis Knowledge Park, A wing, Office No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai – 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com